CinnoRA (Adalimumab)

CinnoRA is used to reduce signs and symptoms of rheumatoid arthritis (RA). Your doctor will decide if CinnoRA can be used alone or in combination with other medications. CinnoRA can also be used in juvenile idiopathic arthritis (≥2 years of age), ulcerative colitis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-infectious uveitis in adults and children (≥2 years of age), Crohn’s disease in adults or children (≥6 years of age), and hidradenitis suppurativa in adults and adolescents (≥12 years of age).

Do not use CinnoRA if:

• You are allergic to adalimumab or any components of the CinnoRA formulation.

• You have severe active infections.

• You have moderate to severe heart failure.

• If you are receiving any other medicines

• If you are scheduled to have any surgery or dental procedures

• Before getting any vaccines

• If you have symptoms such as fever, wound, abnormal bleeding, or feeling extremely tired

• are pregnant or planning to become pregnant

• are breastfeeding or planning to breastfeed

Your physician determines the dosage of your medicine. But the usual dose of CinnoRA is as follows:
CinnoRA has usually prescribed 40 mg every other week, subcutaneously.

• Symptoms of infection (fever, chills, sore throat, flu-like symptoms)

• Injection site reaction (including redness, swelling, localized discoloration, inflammation, and pain)

• Headache

• Skin rash

If any other unpleasant symptoms occurred, inform your doctor or pharmacist.

• Hypersensitivity reactions: CinnoRA may cause hypersensitivity, anaphylactoid reactions, anaphylaxis, or angioedema.

• Lupus-like syndrome: rare autoimmune disorders, including lupus-like syndrome, have been reported. Your doctor will monitor you for any signs or symptoms.

• Multiple sclerosis: Rare cases of exacerbation or new-onset demyelinating disorders (eg, Multiple sclerosis) have been reported. Your doctor will discontinue treatment in patients who develop peripheral or central nervous system demyelinating disorders during treatment.

• Congestive heart failure: Worsening and new-onset heart failure (HF) has been reported.

• Rare cases of pancytopenia and aplastic anemia: have been reported with TNF blockers.

• Rare reactivation of hepatitis B (HBV): has occurred in chronic carriers of the virus, evaluate for HBV before initiation in all patients. Your doctor will monitor you during and for several months following discontinuation of treatment in HBV carriers

• Serious infections: patients receiving adalimumab are at increased risk for serious infections. These include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria. Infections usually developed in patients receiving concomitant immunosuppressive agents (eg, methotrexate, corticosteroids) and may present as disseminated (rather than local) diseases.

• Lymphoma and other malignancies (some fatal): have been reported in children and adolescents receiving TNF-blocking agents.

• Store CinnoRA in a refrigerator (2ºC-8ºC). Do not freeze.

• Each autoinjector is for single use only.

• Keep CinnoRA in the outer carton in order to protect it from light.

• Keep this medicine out of the sight and reach of children.

• Do not use this medicine after the expiry date stated on the carton or device, after “EXP”.